Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2009 - 2026)

Dr Reddys Laboratories has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $46.8 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 71.72% year-over-year to $46.8 million in Q2 2026; TTM through Jun 2026 was $12.6 million, a 96.97% decrease from a year earlier, with the FY2026 full-year figure at $485.5 million, down 30.74% from the prior year.
• Net Income towards Common Stockholders was $46.8 million for Q2 2026 at Dr Reddys Laboratories, up from $4.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $179.0 million in Q3 2023, with the low at -$203.0 million in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is $104.0 million, with a median of $155.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 1352.3% in 2023, then tumbled 221.28% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $117.0 million in 2022, then surged by 41.54% to $165.6 million in 2023, then increased by 1.08% to $167.4 million in 2024, then sank by 221.28% to -$203.0 million in 2025, then soared by 123.08% to $46.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $46.8 million (Q2 2026), $4.0 million (Q1 2026), and -$203.0 million (Q4 2025), per Business Quant data.